ArticleJournal of neuro-oncology2010
Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.
Article in Journal of neuro-oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- MRI-guided intracerebral convection-enhanced injection of gliotoxins to induce focal demyelination in swine.PloS one · 2018Article
- Imaging of Convective Drug Delivery in the Nervous System.Neurosurgery clinics of North America · 2017Review
- Remodeling the blood-brain barrier microenvironment by natural products for brain tumor therapy.Acta pharmaceutica Sinica. B · 2017Review
- Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.BioMed research international · 2017Review
- Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers.Toxins · 2016Review
- MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.Neuro-oncology · 2016Article
- Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.Investigational new drugs · 2016Article
- Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.Neuro-oncology · 2016Review
- Current status of intratumoral therapy for glioblastoma.Journal of neuro-oncology · 2015Article
- Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas.Journal of neurosurgery. Pediatrics · 2014Article
- Differential effects of two MRI contrast agents on the integrity and distribution of rAAV2 and rAAV5 in the rat striatum.Molecular therapy. Methods & clinical development · 2014Article
- Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Which drug or drug delivery system can change clinical practice for brain tumor therapy?Neuro-oncology · 2013Review
- Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.Cancer treatment reviews · 2013Review
- Devices for cell transplantation into the central nervous system: Design considerations and emerging technologies.Surgical neurology international · 2013Article
- Convection enhanced delivery of macromolecules for brain tumors.Current drug discovery technologies · 2012Article
- Efficacy of vincristine administered via convection-enhanced delivery in a rodent brainstem tumor model documented by bioluminescence imaging.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2012Article
- Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.Nuclear medicine and biology · 2012Article
- Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.Neurosurgery · 2011Article
- Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.International journal of cancer · 2011Article
Corrections and comments
- Erratum issuedDosage error in article text
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
A major obstacle in glioblastoma (GBM) therapy is the restrictive nature of the blood-brain barrier (BBB). Convection-enhanced delivery (CED) is a novel method of drug administration which allows direct parenchymal infusion of therapeutics, bypassing the BBB. MR1-1 is a novel recombinant immunotoxin that targets the GBM tumor-specific antigen EGFRvIII and can be delivered via CED infusion. However, drug distribution via CED varies dramatically, which necessitates active monitoring. Gadolinium conjugated to diethylenetriamine penta-acetic acid (Gd-DTPA) is a commonly used MRI contrast agent which can be co-infused with therapies using CED and may be useful in monitoring infusion leak and early distribution. Forty immunocompetent rats were implanted with intracerebral cannulas that were connected to osmotic pumps and subsequently randomized into four groups that each received 0.2% human serum albumin (HSA) mixed with a different experimental infusion: (1) 25 ng/ml MR1-1; (2) 0.1 micromol/ml Gd-DTPA; (3) 25 ng/ml MR1-1 and 0.1 micromol/ml Gd-DTPA; (4) 250 ng/ml MR1-1 and 0.1 micromol/ml Gd-DTPA. The rats were monitored clinically for 6 weeks then necropsied and histologically assessed for CNS toxicity. All rats survived the entirety of the study without clinical or histological toxicity attributable to the study drugs. There was no statistically significant difference in weight change over time among groups (P > 0.999). MR1-1 co-infused with Gd-DTPA via CED is safe in the long-term setting in a pre-clinical animal model. Our data supports the use of Gd-DTPA, as a surrogate tracer, co-infused with MR1-1 for drug distribution monitoring in patients with GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.